Blackstone Life Sciences is putting $250 million to work on a little-known biotech seeking to drastically reduce the number of pills many cystic fibrosis patients have to take each day.
Blackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
Biotech raises $42 million to run Huntington’s disease trial
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
Anthropic teams with Goldman, Blackstone and others on $1.5 billion AI venture targeting PE-owned firms
Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
Blackstone and Goldman among backers for $1.5bn Anthropic JV
Shopping americano per Angelini: scommessa da 3,5 miliardi su Catalyst
In a milestone for ALS, a treatment helps some patients improve
Angelini to buy Catalyst in $4B play for rare neuro drugs
